Skip Sub Menu

Profile of a Pharmacy Innovator: Rachel Digmann

Rachel Digmann, PharmD., BCPS

Rachel received her Doctor of Pharmacy from Drake University and completed a specialty residency in Primary Care at the University of Iowa. She practiced as a Clinical Pharmacy Specialist in Primary Care at Kaiser Permanente Colorado for many years. Eventually, she and her family decided to relocate back to Iowa, where she had the opportunity to expand her pharmacy career. She held various clinical and administrative pharmacy positions including: Clinical Operations Manager for a PBM, Director of Clinical Pharmacy for a health insurance company, and Assistant Chief of Pharmacy at a VA hospital. In 2012, she accepted the position as Telligen’s Clinical Pharmacy Specialist and began work on the state of Iowa Quality Improvement Organization (QIO) contract. She is currently the Medication Safety & Program Lead for the Quality Innovation Network National Coordinating Center contract at Telligen.

Under the federal Centers for Medicare and Medicaid contract, Rachel is involved in the design and implementation of measures used to evaluate ADE outcomes using national Part D and Part A claims. She serves as a consultant to others on viable quality improvement options and potential business opportunities based on data. She also works to identify methods for standardizing the measurement of ADE outcomes and laying the groundwork for a pharmacy-driven quality improvement market. Rachel and her team have undertaken exploratory analysis and are a phase of expansion for additional testing and outcomes.

With the evolution of payment from fee-for-service reimbursement to quality-based reimbursement, Rachel believes pharmacists are in a unique position to create new business models based on their access to patient information and ability to integrate into care transitions. Her experience and professional leadership have led her to value an innovative approach in the changing health care environment. Rachel recognizes, “the collection of data and the ability to attribute improved patient outcomes to pharmacy interventions is the key to making the new business models successful.”